Hec-016
CAR T-Cell Therapy
Shenzhen Fifth People's HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the CAR T-Cell Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isoproterenol University of Arizona | Early Phase 1 | C |
Bisoprolol Fumarate University of Arizona | Early Phase 1 | C |
NADOLOL University of Arizona | Early Phase 1 | C |
CARVEDILOL University of Arizona | Early Phase 1 | C |
Roflumilast University of Arizona | Early Phase 1 | C |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →